1
0
0
(1 - 16 von 16
)
Dr.-Ing. Sebastian HarderGRIN Verlag
www.grin.com
Sebastian Harder. Info. Auteur depuis: Textes (3). Titre: Motivationstheorien und ihre Anwendung · Motivationstheorien und ihre Anwendung. N° de ... Sebastian Harder. Info. Auteur depuis: Textes (3). Titre: Motivationstheorien und ihre Anwendung · Motivationstheorien und ihre Anwendung. N° de ...
Autorenprofil | Dr.-Ing. Sebastian Harder | 3 eBooks | GRIN
www.grin.com
Sebastian Harder. eBooks: 3. …
Sebastian Harder likes an article.
Direct oral anticoagulants for the treatment of venous...
www.sciencedirect.com
von H Riess · · Zitiert von: 36 — Sebastian Harder, MD, has been a lecturer in Clinical Pharmacology at the Medical Faculty of the Goethe-University Frankfurt am Main since 1996, ... › pii
Pharmacokinetic and pharmacodynamic evaluation of rivaroxabanthrombosisjournal.biomedcentral.com › articles
thrombosisjournal.biomedcentral.com
· Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Sebastian Harder.
Goethe-Universität â QB 9 (Klinische Pharmakologie)
www.uni-frankfurt.de
SpletProf. Dr. Sebastian Harder -frankfurt.de Prof. Dr. Rolf Nüsing Stellvertreter, Verantwortlicher Web-CT -frankfurt.de Tel.: â¦
Autorenprofil | Dr.-Ing. Sebastian Harder | GRIN
www.grin.com
Unter allen Autoren verlosen wir dieses Jahr ein iPhone X im Wert von Euro. Jede neue Arbeit ist ein Los!
HDAC-inhibition counteracts everolimus resistance in renal cell...
molecular-cancer.biomedcentral.com
... Igor Tsaur,; Jens Mani,; Sebastian Harder,; Georg Bartsch,; Axel Haferkamp and; Roman A BlahetaEmail author. Molecular Cancer : ...
OPUS 4 | HDAC-inhibition counteracts everolimus resistance in renal...
publikationen.ub.uni-frankfurt.de
HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by ... Karen Nelson, Michael Reiter, Igor Tsaur, Jens Mani, Sebastian Harder, ...
Innovation and Economic Growth in China - Evidence from Patent - GRIN
www.grin.com
Innovation and Economic Growth in China - Evidence from Patent Statistics - Economics / Economic Cycle and Growth - Master's Thesis ebook € - GRIN
Primary care management for optimized antithrombotic treatment...
implementationscience.biomedcentral.com
Andrea SiebenhoferEmail author,; Lisa R Ulrich,; Karola Mergenthal,; Ina Roehl,; Sandra Rauck,; Andrea Berghold,; Sebastian Harder, ...
Literaturverzeichnis
www.biophys.uni-frankfurt.de
Literaturverzeichnis Mäntele Sebastian Harder, Christian Friedrich Weber, Doan Baykut, Dirk Meininger, Harald Keller, Anton Moritz, and Werner Maentele.
Motivationstheorien und ihre Anwendung - GRIN
www.grin.com
Motivationstheorien und ihre Anwendung - Führung und Personal / Sonstiges - Seminararbeit ebook 11,99 € - GRIN
Phase I clinical study of the recombinant antibody-toxin scFv(FRP5 ...breast-cancer-research.biomedcentral.com › bcr1390
breast-cancer-research.biomedcentral.com
· Sebastian Harder,; Sascha Hövelmann,; Elke Jäger,; Salah-Eddin Al ... Sebastian Harder. G2M Cancer Drugs AG, Frankfurt am Main, Germany.
Stoy, Sebastian - FreiDok plusfreidok.uni-freiburg.de › pers
freidok.uni-freiburg.de
Stoy, Sebastian ; Harder, Nick · ORCID logo ; Heinemann, Christoph ; Kaiser, Michael Markus ; Sandhaas, Anna et al. Professur für Technologien der ...
The Efficient Market Hypothesis and its Application to Stock Markets...
www.grin.com
The Efficient Market Hypothesis and its Application to Stock Markets - Dr.-Ing. Sebastian Harder - Studienarbeit - BWL - Investition und Finanzierung -...
Phase I clinical study of the recombinant antibody toxin...
breast-cancer-research.biomedcentral.com
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Gunter von Minckwitz,; Sebastian Harder,; Sascha Hövelmann,; Elke Jäger,; Salah- Eddin Al-Batran,; Sibylle Loibl,; Akin Atmaca,; Christian Cimpoiasu,; Antje Neumann, ...
sortiert nach Relevanz / Datum